Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412501 · ClinicalTrials.gov registry record · NA
Medtronic Resolute Onyx 2.0 mm Clinical Study
A NA study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- NA
- Development phase
- 101
- Enrollment target
NCT02412501 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 101 participants.
The verdict
NCT02412501, a NA study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries that allows the use of a 2.0 mm diameter stent.
Interventions
- DEVICE Resolute Onyx Stent - 2.0 mm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2015-04-06 |
| Est. Completion | 2019-02-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02412501
The ClinicalTrials.gov registry entry for NCT02412501 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Resolute Onyx Stent - 2.0 mm is the first listed.
NCT02412501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02412501 about?
NCT02412501 is a clinical study titled "Medtronic Resolute Onyx 2.0 mm Clinical Study". The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries that allows the use of a 2.0 mm diameter stent.
What is the current status of trial NCT02412501?
This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2015-04-06. Estimated completion is 2019-02-21.
What interventions are being tested in trial NCT02412501?
The interventions under investigation include: Resolute Onyx Stent - 2.0 mm (DEVICE).
Who is sponsoring clinical trial NCT02412501?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.